Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 549 participants.
Also called NCT05462145
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 549 participants
- Sponsor
- Registry
-
NCT05462145
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Czechia, Germany
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05462145. Allocation not applicable; no masking; primary purpose treatment. Start 2023-03-09 (actual); primary completion 2029-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
- Acronym
- PULSAR
- Condition
- Paroxysmal Atrial Fibrillation
- Condition
- Persistent Atrial Fibrillation
- Intervention (Device)
- Globe Pulsed Field System
- Lead sponsor
- Kardium Inc.
Record details
- Record id
cardio:ct-nct05462145- Content hash
a28cb3e6abe93e77984de05724e4a8ef9cff3ff1e88ebe6160945e597681e8ae